Inactive Instrument

Analyst Reco. GTx, Inc. Nasdaq

Equities

US40052B1089

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating	Apr. 15	MT
Brookline Capital Upgrades Oncternal Therapeutics to Buy From Hold, Price Target is $2	Dec. 04	MT
HC Wainwright Upgrades Oncternal Therapeutics to Buy From Neutral, Price Target is $2	23-09-18	MT
Maxim Downgrades Oncternal Therapeutics to Hold From Buy	23-04-04	MT
Oppenheimer Downgrades Oncternal Therapeutics to Perform From Outperform, Removes $9 Price Target	23-04-04	MT
Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy	23-04-04	MT
Cantor Fitzgerald Adjusts Price Target on Oncternal Therapeutics to $1.30 From $4, Keeps Overweight Rating	23-04-04	MT
HC Wainwright Downgrades Oncternal Therapeutics to Neutral From Buy	23-04-04	MT
Oppenheimer Adjusts Oncternal Therapeutics Price Target to $9 From $14, Maintains Outperform Rating	23-03-22	MT
Cantor Fitzgerald Initiates Oncternal Therapeutics With Overweight Rating, $4 Price Target	22-12-22	MT
Maxim Initiates Oncternal Therapeutics at Buy, Sets Price Target at $3.50	22-05-10	MT
BTIG Starts Oncternal Therapeutics at Buy With $5 Price Target	22-02-24	MT
ONCTERNAL THERAPEUTICS : Oppenheimer Adjusts Oncternal Therapeutics PT to $16 From $14, Maintains Outperform Rating	21-04-16	MT
ONCTERNAL THERAPEUTICS : Oppenheimer Starts Oncternal Therapeutics at Outperform with $14 Price Target	21-04-07	MT
ONCTERNAL THERAPEUTICS : Brookline Capital Initiates Coverage on Oncternal Therapeutics With Buy Rating, $16 Price Target	21-03-30	MT
ONCTERNAL THERAPEUTICS : Northland Starts Oncternal Therapeutics at Outperform With $21 Price Target	21-02-23	MT
Oncternal Therapeutics, Inc. Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma	20-03-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer